Search

Your search keyword '"Claxton, J'Neka"' showing total 128 results
Start Over Author "Claxton, J'Neka" Publication Year Range Last 10 years
128 results on '"Claxton, J'Neka"'

14. SOCIAL AND EDUCATIONAL OUTCOMES AMONG ADULTS WITH CONGENITAL HEART DISEASE BY SEVERITY: A REPORT FROM THE CONGENITAL HEART DISEASE PROJECT TO UNDERSTAND LIFELONG SURVIVOR EXPERIENCE (CHD PULSE)

Author

Claxton, J'Neka, primary, Velani, Romie, additional, Ilardi, Dawn, additional, Knight, Jessica, additional, Jacobs, Jeffrey P., additional, McHugh, Kimberly E., additional, Schwartz, Andrew Dailey, additional, Anderson, Susan, additional, Kuo, Krisy, additional, Aldoss, Osamah, additional, Canter, Charles E., additional, Gaitonde, Mansi, additional, John, Anitha S., additional, Hiremath, Gurumurthy, additional, Marino, Bradley S., additional, Overman, David M., additional, Raghuveer, Geetha, additional, Spector, Logan, additional, Fundora, Michael Phillip, additional, Kochilas, Lazaros, additional, and Oster, Matthew, additional

Published
2023
Full Text
View/download PDF

15. OUTCOMES AMONG PATIENTS IN AND OUT OF CARDIAC CARE: THE CONGENITAL HEART DISEASE PROJECT TO UNDERSTAND LIFELONG SURVIVOR EXPERIENCE (CHD PULSE)

Author

Oster, Matthew, primary, Claxton, J'Neka, additional, Velani, Romie, additional, Kuo, Krisy, additional, Ilardi, Dawn, additional, Aldoss, Osamah, additional, Canter, Charles E., additional, Gaitonde, Mansi, additional, John, Anitha S., additional, Hiremath, Gurumurthy, additional, McHugh, Kimberly E., additional, Overman, David M., additional, Raghuveer, Geetha, additional, Jacobs, Jeffrey P., additional, Marino, Bradley S., additional, Spector, Logan, additional, and Kochilas, Lazaros, additional

Published
2023
Full Text
View/download PDF

23. LONG-TERM TRANSPLANT-FREE SURVIVAL AFTER CONGENITAL HEART SURGERY

Author

Kochilas, Lazaros, primary, Thomas, Amanda, additional, Zhang, Chao, additional, Claxton, J’Neka, additional, McCracken, Courtney, additional, Louis, James St, additional, Moller, James, additional, Alonso, Alvaro, additional, Spector, Logan, additional, Shaw, Fawwaz, additional, and Huang, Yijian, additional

Published
2021
Full Text
View/download PDF

37. Abstract MP17: Comorbidity Type and Risk of Hospitalization and Death in Patients With Atrial Fibrillation

Author

Chamberlain, Alanna M, primary, Alonso, Alvaro, additional, Noseworthy, Peter, additional, Jiang, Ruoxiang, additional, Weston, Susan, additional, Lutsey, Pamela, additional, Chen, Lin, additional, O’Neal, Wesley, additional, Bengtson, Lindsay, additional, Norby, Faye, additional, Claxton, J’Neka, additional, MacLehose, Richard, additional, and Roger, Veronique, additional

Published
2019
Full Text
View/download PDF

46. Associations of anger, vital exhaustion, anti-depressant use, and poor social ties with incident atrial fibrillation: The Atherosclerosis Risk in Communities Study

Author

Garg, Parveen K, Claxton, J’Neka S, Soliman, Elsayed Z, Chen, Lin Y, Lewis, Tené T, Mosley, Thomas, and Alonso, Alvaro

Abstract

Background We examined the relationships of anger, vital exhaustion, anti-depressant use, and poor social ties with incident atrial fibrillation in a biracial cohort of middle and older-aged adults.Methods This analysis included 11,445 Atherosclerosis Risk in Communities Study participants who were free of atrial fibrillation at baseline in 1990–1992. Vital exhaustion was assessed at baseline and defined as a score in the highest quartile on the 21-item Vital Exhaustion Questionnaire. Baseline anti-depressant use was self-reported. The Spielberger Trait Anger Scale to assess anger and both the Interpersonal Support Evaluation List and the Lubben Social Network Scale to assess social ties were also administered at baseline. The primary outcome was incident atrial fibrillation throughout 2016, identified by electrocardiogram, hospital discharge coding of atrial fibrillation, and death certificates.Results A total of 2220 incident atrial fibrillation cases were detected over a median follow-up of 23.4 years. After adjusting for age, race-center, sex, education, and height, participants in the 4th Vital Exhaustion Questionnaire quartile (referent = 1st Vital Exhaustion Questionnaire quartile) and those reporting anti-depressant use were at increased risk for atrial fibrillation (hazard ratio = 1.45, 95% confidence interval 1.29–1.64 for Vital Exhaustion Questionnaire; hazard ratio = 1.37, 95% confidence interval 1.11–1.69 for anti-depressant use). The increased atrial fibrillation risk observed for 4th Vital Exhaustion Questionnaire quartile participants remained significant after additional adjustment for relevant comorbidities (hazard ratio = 1.20; confidence interval 1.06–1.35). No significant associations were observed for anger or poor social ties with development of atrial fibrillation.Conclusions Vital exhaustion is associated with an increased risk of incident atrial fibrillation.

Published
2024
Full Text
View/download PDF

47. Provider Specialty, Anticoagulation, and Stroke Risk in Patients With Atrial Fibrillation and Cancer.

Author

O'Neal, Wesley T., Claxton, J'Neka S., Sandesara, Pratik B., MacLehose, Richard F., Chen, Lin Y., Bengtson, Lindsay G.S., Chamberlain, Alanna M., Norby, Faye L., Lutsey, Pamela L., and Alonso, Alvaro

Subjects
*ATRIAL fibrillation, *CANCER patients, *CARDIOLOGY, *ANTICOAGULANTS, STROKE risk factors
Abstract

Background: It is unknown whether early cardiology involvement shortly after atrial fibrillation (AF) diagnosis is associated with favorable outcomes in AF patients who have cancer.Objectives: The purpose of this study was to examine the relationship between early cardiology involvement after AF diagnosis in patients with history of cancer.Methods: This study examined associations of early cardiology involvement with oral anticoagulation use, stroke, and bleeding among nonvalvular AF patients (n = 388,045; mean age 68 ± 15 years; 59% male) with a history of cancer (past or active) from the MarketScan database (2009 to 2014). International Classification of Disease-9th Revision-Clinical Modification codes in any position were used to identify cancer diagnosis prior to AF diagnosis. Provider specialty and filled anticoagulant prescriptions 3 months prior to and 6 months after AF diagnosis were obtained. Poisson regression models were used to compute the probability of an oral anticoagulant prescription fill, and Cox regression was used to estimate the risks of stroke and major bleeding.Results: A total of 64,016 (17%) AF patients had a history of cancer. Cardiology involvement was less likely to occur among patients with a history of cancer than those without (relative risk [RR]: 0.92 [95% confidence interval (CI): 0.91 to 0.93]). Patients with history of cancer were less likely to fill prescriptions for anticoagulants (RR: 0.89 [95% CI: 0.88 to 0.90]) than those without cancer, and similar results were observed across cancer types. Patients with cancer were more likely to fill prescriptions for anticoagulants (RR: 1.48 [95% CI: 1.45 to 1.52]) if seen by a cardiologist. A reduced risk of stroke (hazard ratio: 0.89 [95% CI: 0.81 to 0.99]) was observed among all cancer patients who were seen by a cardiology provider, without an increased risk of bleeding (hazard ratio: 1.04 [95% CI: 0.95 to 1.13]). Similar results were observed when the analysis was stratified by active versus remote history of cancer.Conclusions: Although AF patients with cancer were less likely to see a cardiologist, or fill anticoagulant prescriptions, cardiology involvement was associated with increased anticoagulant prescription fills and favorable AF-related outcomes in AF patients with cancer. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Abstract 15282: COVID-19 Cases, Hospitalizations, and Vaccination Among Adults With Congenital Heart Disease

Author

Oster, Matthew, Velani, Romie N, Claxton, J'Neka S, Kuo, Kristina W, Aldoss, Osamah, Canter, Charles E, Gaitonde, Mansi, John, Anitha, Malikarjun, gurumurthy H, McHugh, Kimberly, Overman, David M, Raghuveer, Geetha, Spector, Logan, and Kochilas, Lazaros

Abstract

Background:There are conflicting data as to whether congenital heart disease (CHD) should be considered a condition that places a person at high risk of severe illness from COVID-19. The objective of our study was to compare COVID-19 cases, hospitalization rate, and vaccine uptake among adults with history of cardiac intervention vs. the general US adult population.Methods:We performed a cross-sectional study of adults using survey data from the Congenital Heart Disease Project to Understand Lifelong Survivor Experience (CHD PULSE). This survey, conducted in 2021-2022, queried CHD survivors regarding a variety of domains, including history of COVID-19 infection and vaccination. Adults with a history of surgical, catheter, or electrophysiologic intervention at 1 of 8 Pediatric Cardiac Care Consortium centers were eligible for inclusion. Results were limited to those aged 18-49 years to allow comparison to age-specific data from the US Centers for Disease Control and Prevention.Results:Among 1,277 respondents (20.2% response rate), the median age was 32 years (IQR: 27-38 years), the majority were female (55.6%), and the most common race/ethnicity was Non-Hispanic White (89.9%). There was no difference in history of a positive COVID-19 test in persons with CHD compared to adults of a similar age (26.8% vs 28.1%, p=0.86). However. those with CHD and COVID-19 were significantly more likely to require hospitalization than adults in the general population with COVID-19 (1.75% vs. 0.26%, p=0.004) (Figure). Regarding COVID-19 vaccination, 76.5% of CHD PULSE respondents reported a history of at least 1 COVID-19 vaccine, with no differences vs. the general population when compared by age (p=0.99).Conclusions:Given higher hospitalization rates among adults with CHD and COVID-19, CHD should be considered a medical condition that places one at increased risk of severe COVID-19. These findings underscore the importance of COVID-19 vaccination in this population.

Published
2022
Full Text
View/download PDF

50. Abstract 15588: Effect of Covid-19 on the Mortality of Patients With Congenital Heart Disease

Author

Yang, Yanxu, Huang, Eugene, Claxton, J'Neka, Kuo, Kristina W, Oster, Matthew, and Kochilas, Lazaros

Abstract

Introduction:Cardiovascular conditions have been recognized as risk factors for poor outcomes in association with COVID-19. However, the effect of the COVID-19 pandemic on different severity types of congenital heart disease (CHD) patients remains unknown. This study aims to examine whether patients with history of interventions for CHD experienced a higher mortality risk during the COVID-19 pandemic.Methods:This is a retrospective cohort study using data from the Pediatric Cardiac Care Consortium (PCCC). We included patients having US residence and direct identifiers, who were enrolled between 1982 and 2003 after undergoing transcatheter or surgical interventions for CHD. The observation window (2017-2020) was divided to a pre-SARSV2 and SARSV2 exposure period defined around the state specific onset of COVID-19 disease in 2020. Patients were categorized as having mild, moderate, severe-2 ventricle (2V) or single ventricle (SV) CHD. Standardized mortality ratios (SMRs) were used to describe the observed risk of mortality in CHD patients compared to the age- and sex-adjusted rates from the general U.S. population. Multivariable analysis was conducted using time-varying covariate Cox proportional hazards model with adjustment for age, sex and severity of CHD.Results:A total of 50,138 patients with history of interventions for CHD were included. Pooled pre-SARSV2 SMR was 2.38 [95% CI: 2.06, 2.75], while the SARSV2-exposure SMR was 2.07 [95% CI: 1.78, 2.35] (not significantly different). No significant differences in pooled SMRs were found by severity of CHD. The adjusted hazard risk for all-cause mortality in the SARSV2-exposure vs pre-SARSV2 period did not increase for patients with CHD (aHR: 0.59, 95%CI:0.19 - 1.84), and we did not find any differences in risk by severity subgroups or sex of patients.Conclusion:In this large cohort study monitoring long term outcomes after interventions for CHD, we could not detect any evidence of increased risk for all-cause mortality among this population during the early part of the COVID-19 pandemic. Additional data will be required over longer period to fully understand the impact of COVID-19 on adults with repaired CHD.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results